Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 312 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 3TC Clear all

Conditions: HIV Infections
Interventions: Abacavir sulfate, Emtricitabine, Lamivudine, Lopinavir/ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York • Stony Brook, New York + 1 more

Conditions: HIV Infections
Interventions: Atazanavir/ Stavidine / Lamivudine, Atazanavir-Ritonavir/ Stavidine / Lamivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Call For Information, New Jersey

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: CPI-1189; Drug
Lead sponsor: Centaur Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV-1-infection
Interventions: GS-3242, BVY, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more

Conditions: HIV-1 Infection
Interventions: RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 63
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio

Conditions: HIV Infections
Interventions: Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 12
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more

Conditions: HIV-1
Interventions: Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more

Conditions: HIV Infections
Interventions: 3TC, TDF, NLV; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 15 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 18
States / cities: La Jolla, California • San Francisco, California • New Haven, Connecticut + 13 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 42
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 33 more

Conditions: Hepatitis B Virus Associated Liver Disease
Interventions: Hepatitis B Immune Globulin (Boca HBVIg); Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 11
States / cities: San Francisco, California • Gainesville, Florida • Jacksonville, Florida + 7 more

Conditions: High Grade Glioma
Interventions: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy; Procedure · Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nevirapine, Lamivudine, Stavudine, Didanosine; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: TRIUMEQ, DOVATO; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: Trizivir, atazanavir, Combivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 43
States / cities: Bakersfield, California • Los Angeles, California • Oakland, California + 35 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine, Stavudine, Zidovudine, Didanosine, Lyme Disease Vaccine Recombinant OspA, Haemophilus B Conjugate Vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio

Conditions: HIV Infection
Interventions: efavirenz, tenofovir, abacavir/lamivudine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 58
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 42 more

Conditions: Colorectal Cancer Metastatic
Interventions: Lamivudine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infection
Interventions: Highly active antiretroviral therapy (HAART); Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 26
States / cities: Alhambra, California • Los Angeles, California • San Diego, California + 20 more

Conditions: HIV-1
Interventions: Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Syracuse, New York • Memphis, Tennessee

Conditions: HIV-DDI
Interventions: Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Boston, Massachusetts

Search by objective public record fields.

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

Study of GS-3242 in Participants With HIV-1; Substudy-05

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

STARLITE for Unresectable High-Grade Gliomas

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

Study of Anti-HIV Therapy Intensification

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Interaction With HIV Antiretroviral Agents